February 14, 2013 — Bayer HealthCare announced that the New Drug Application (NDA) for its investigational oncology compound Radium Ra 223 Dichloride (radium-223) has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA). The application is currently under review for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

The FDA grants priority review to medicines that provide a treatment where little or no adequate therapy exists. Under the Prescription Drug User Fee Act (PDUFA), the FDA aims to complete its review within six months of the 60-day filing receipt of the NDA submission (eight months total), rather than the standard 12-month review cycle.

In September 2009, Bayer signed an agreement with Algeta ASA (Oslo, Norway) for the development and commercialization of radium-223. Under the terms of the agreement, Bayer will develop, apply for health authority approvals worldwide, and commercialize radium-223 globally. Algeta will co-promote radium-223 with Bayer in the United States.

For more information: www.bayer.com 

Related Content

Videos | Radiation Therapy

Jeffrey T. Chapman, a medical student at the University of Texas Southwestern Medical Center, Explains how watching ...

Time November 24, 2021
arrow
Videos | Radiopharmaceuticals and Tracers

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

Time November 17, 2021
arrow
Videos | Radiation Therapy

The Elekta Harmony radiotherapy system gained FDA clearance in the summer of 2021 and was on display for the first time ...

Time November 17, 2021
arrow
News | Radiation Therapy

November 17, 2021 — Radiation can be a powerful cancer therapy, but it doesn’t work for everyone. A new study identifies ...

Time November 17, 2021
arrow
Videos | Radiation Oncology

This is a model of the Toshiba ion beam radiation therapy system at the American Society of Radiation Oncology (ASTRO) ...

Time November 16, 2021
arrow
News | Prostate Cancer

November 16, 2021 — A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 ...

Time November 16, 2021
arrow
Videos | Radiation Oncology

Walter Curran, Jr. M.D., FACR, FASCO, GenesisCare global chief medical officer, discusses three technologies that are ...

Time November 16, 2021
arrow
Videos | Radiation Oncology

This is an example of a multileaf collimator (MLC) on the Accuray Thomotherapy radiation therapy system at the American ...

Time November 16, 2021
arrow
Videos | Radiation Therapy

Anthony Zietman, M.D., interim chief, radiation oncology, Mass General Cancer Center, and former president of the ...

Time November 15, 2021
arrow
Videos | Radiation Therapy

Siemens and Philips demonstrated examples of new imaging software to convert MRI datasets into synthetic computed ...

Time November 15, 2021
arrow
Subscribe Now